Compare INSP & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSP | TMDX |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.9B |
| IPO Year | 2018 | 2019 |
| Metric | INSP | TMDX |
|---|---|---|
| Price | $138.09 | $136.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 10 |
| Target Price | $127.07 | ★ $133.00 |
| AVG Volume (30 Days) | ★ 1.5M | 835.5K |
| Earning Date | 11-03-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 34.77 | ★ 170.70 |
| EPS | 1.48 | ★ 2.54 |
| Revenue | ★ $882,622,000.00 | $566,354,000.00 |
| Revenue This Year | $14.97 | $38.84 |
| Revenue Next Year | $11.81 | $20.43 |
| P/E Ratio | $92.68 | ★ $53.83 |
| Revenue Growth | 16.81 | ★ 41.20 |
| 52 Week Low | $70.77 | $55.00 |
| 52 Week High | $216.01 | $156.00 |
| Indicator | INSP | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 76.95 | 54.31 |
| Support Level | $132.39 | $133.50 |
| Resistance Level | $142.56 | $156.00 |
| Average True Range (ATR) | 7.26 | 8.50 |
| MACD | 3.75 | 0.41 |
| Stochastic Oscillator | 90.18 | 55.98 |
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.